

Lablytica Life Science and Svar Life Science Forge Strategic Partnership to Deliver Integrated Bioanalytical Services with Advanced LC-MS/MS Capabilities

Uppsala, Sweden – June 10, 2025 – Lablytica Life Science, an independent Swedish contract research organization (CRO) specialized in regulated bioanalysis, is pleased to announce a strategic partnership with Svar Life Science, a trusted provider of versatile products and assay solutions for drug development and clinical diagnostics. This collaboration strengthens Lablytica's ability to offer integrated, end-to-end bioanalytical services by aligning with Svar's well-established expertise in ligand-binding and cell-based assay platforms.

The partnership brings together Lablytica's advanced Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) capabilities and Svar's broad CRO service portfolio, creating a powerful combination that supports both small and large molecule drug development across all phases—from discovery through clinical trials.

"We are proud to partner with Svar Life Science in a shared mission to support pharmaceutical and biotech companies with high-quality, science-driven analytical solutions," said David Pekar, CEO of Lablytica Life Science. "This partnership allows us to offer clients a seamless and scalable approach to bioanalysis, combining our LC-MS/MS expertise with Svar's proven platforms to meet today's complex development needs."

Through this collaboration, clients gain access to Lablytica's GLP-certified LC-MS/MS services for pharmacokinetics (PK), pharmacodynamics (PD), biomarker quantification, and therapeutic drug monitoring—fully compliant with FDA, EMA, and ICH M10 guidelines. Together, Lablytica and Svar deliver increased analytical depth, operational flexibility, and regulatory excellence.

"Our joint offering enables us to respond to growing industry demands for sensitivity, specificity, and compliance across therapeutic modalities," said Anna Karaszewska, Product Manager, CRO Services at Svar Life Science. "Lablytica's solid track record in mass spectrometry complements our bioanalytical services perfectly, and positions us as a strong integration partner for clients developing complex biologics and small molecules."

Highlights of the Partnership:

- **Complementary Expertise:** Integration of LC-MS/MS with ligand-binding and cell-based assays.
- **Regulatory Assurance:** GLP- and GCP-compliant services meeting global regulatory standards.
- **Broad Therapeutic Coverage:** Supporting biologics, small molecules, ADCs, peptides, oligonucleotides, and more.
- **Client-Focused Approach:** Flexible, transparent collaboration tailored to project needs.
- **Expanded Market Reach:** Improved accessibility for biotech, pharma, and CRO partners across Europe.

This collaboration is an important step in Lablytica's long-term growth strategy to expand its reach, enhance its service offering, and help accelerate the development of next-generation therapies through robust, compliant, and innovative bioanalytical support.

About Lablytica Life Science

Lablytica is an independent CRO based in Uppsala, Sweden, with over a decade of experience in regulated bioanalysis. Specializing in LC-MS/MS-based sample analysis for plasma, tissue, and urine, Lablytica operates under full GLP compliance and is part of the Swedish OECD GLP inspection program by SWEDAC. Originally a spin-off from Recipharm OT Chemistry, Lablytica became a stand-alone company under Center for Translational Research in 2019.

Learn more at www.lablytica.com

About Svar Life Science

Svar Life Science AB is a Swedish company dedicated to enabling personalized medicine through innovative tools for drug development and companion diagnostics. With over 30 years of experience across the diagnostic value chain, Svar provides trusted answers from discovery to diagnosis through high-quality products, technologies, and laboratory services.

Learn more at www.svarlifescience.com